

Axovant Sciences Ltd.
Form 3
July 13, 2016

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol									
Â Lo Andrew		(Month/Day/Year)	Axovant Sciences Ltd. [AXON]									
(Last)	(First)	(Middle)	07/08/2016									
C/O ROIVANT SCIENCES LTD.,Â CLARENDON HOUSE 2 CHURCH STREET			4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)								
(Street)	(Check all applicable)											
	<input type="checkbox"/> Director	<input checked="" type="checkbox"/> 10% Owner										
	<input type="checkbox"/> Officer	<input type="checkbox"/> Other	6. Individual or Joint/Group Filing(Check Applicable Line)									
	(give title below)		(specify below)									
HAMILTON,Â D0Â HM11												
(City)	(State)	(Zip)										
<table border="0"> <tr> <td>1. Title of Security (Instr. 4)</td> <td>2. Amount of Securities Beneficially Owned (Instr. 4)</td> <td>3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)</td> <td>4. Nature of Indirect Beneficial Ownership (Instr. 5)</td> </tr> <tr> <td>Common Shares, \$0.00001</td> <td>75,000,000</td> <td>I</td> <td>See footnote. <u>(1)</u> <u>(2)</u></td> </tr> </table>					1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)	Common Shares, \$0.00001	75,000,000	I	See footnote. <u>(1)</u> <u>(2)</u>
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)									
Common Shares, \$0.00001	75,000,000	I	See footnote. <u>(1)</u> <u>(2)</u>									

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
--	--	---	---	---	---

Edgar Filing: Axovant Sciences Ltd. - Form 3

Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)
------------------	-----------------	-------	----------------------------	----------	---------------------------------------

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Lo Andrew C/O ROIVANT SCIENCES LTD. CLARENDON HOUSE 2 CHURCH STREET HAMILTON, ONTARIO L8M 1H1	X	X	X	X

Signatures

/s/ Andrew Lo 07/13/2016
 **Signature of Date
 Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 These Common Shares are directly beneficially owned by Roivant Sciences Ltd. ("Roivant"). Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (1) (each an "Independent Director" and collectively the "Independent Directors"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent director, that sole Independent Director.
 The reporting person was appointed as an Independent Director of Roivant effective July 8, 2016. Because the approval of the reporting person as an Independent Director is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have (2) sole dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein.

^
Remarks:
 Exhibit 24.1 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.